ScreenerHero

ENGNenGene Holdings Inc. Common Stock

NAS · US · Healthcare · Biotechnology · engene.com
1.780USDMkt Cap: 119.24M $P/E: —

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap119.24M $
Enterprise Value-105.87M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-117.30M $
Revenue/Share—
Last Price1.780 USD
Fiscal Year EndOct 2025
MR QuarterApr 2026
Employees81
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.27
PEG—
EV/EBITDA0.80
EV/Revenue—
P/S—
P/B0.47
EPS (TTM)-2.18
EPS (Forward)-1.40
52W Range
1.77033% of range1.800
52W High1.800 USD
52W Low1.770 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-69.94%
ROA-52.97%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-99.24M $
CapEx (TTM)1.49M $
FCF Margin—
FCF Yield-58.09%
Net Debt-225.11M $
Net Debt/EBITDA1.71
Balance Sheet
Debt/Equity0.19
Current Ratio12.57
Quick Ratio12.17
Book Value/Sh3.809 USD
Cash/Share3.858 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.7 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.286 USD
Upside (mean)+84.6%
Target Range2.000 USD – 5.000 USD
$2.000+84.6% to mean$5.000
# Analysts7
Ownership
Shares Out.66.99M
Float32.73M
Insiders0.10%
Institutions84.00%
Short Interest
Short Ratio1.8d
Short % Float3.19%
Short % Out.2.59%
Shares Short1.73M
Short (prev mo.)1.14M
Technical
SMA 501.790 (-0.6%)
SMA 2005.913 (-69.9%)
Beta-0.28
S&P 52W Chg19.18%
Avg Vol (30d)241.44K
Avg Vol (10d)815.84K
Technical Indicators
RSI (14)48.1
MACD-0.0317
MACD Signal-0.0439
MACD Hist.+0.0122
BB Upper1.853 USD
BB Middle1.765 USD
BB Lower1.677 USD
BB Width9.96%
ATR (14)0.0868 USD
Vol Ratio (20d)0.36x